Newsroom

Dec. 1, 2021, The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.

Nov. 30, 2021, Sera Prognostics announced that Sandra A. J. Lawrence has joined the Sera Board of Directors.

Nov 8,2021, Sera Prognostics announced that Zhenya Lindgardt has joined the Sera Board of Directors.

Nov. 4, 2021, Sera Prognostics announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs.

November 3, 2021, Sera Prognostics announced the publication of a rigorous  validation of a clinical decision point at spontaneous preterm birth (sPTB) risk of 15%, as determined by the company’s PreTRM® test.

Nov. 2, 2021, Sera Prognostics announced a partnership with PreemieWorld, GLO Preemies, and the Alliance for Black NICU Families, leading organizations all geared to empowering and supporting families impacted by preterm birth.

October 27, 2021- The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time.

September 28, 2021- Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

September 15, 2021- Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company.

September 14, 2021- Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs.